Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	MHC class I receptor activity	LILRB2 KIR3DL1 KIR3DS1 LILRA4	1.13e-06	18	90	4	GO:0032393
GeneOntologyMolecularFunction	inhibitory MHC class I receptor activity	LILRB2 KIR3DL1 LILRA4	1.89e-05	12	90	3	GO:0032396
GeneOntologyMolecularFunction	MHC class Ib protein binding	LILRB2 KIR3DL3 KIR3DL1	4.75e-05	16	90	3	GO:0023029
GeneOntologyMolecularFunction	MHC class Ib receptor activity	LILRB2 KIR3DL3 KIR3DL1	8.14e-05	19	90	3	GO:0032394
GeneOntologyMolecularFunction	immune receptor activity	LILRB2 KIR3DL3 KIR3DL1 KIR3DS1 LEPR LILRA4	1.02e-04	165	90	6	GO:0140375
GeneOntologyMolecularFunction	MHC protein binding	LILRB2 KIR3DL3 KIR3DL1 TAPBP	1.36e-04	58	90	4	GO:0042287
GeneOntologyMolecularFunction	HLA-B specific inhibitory MHC class I receptor activity	LILRB2 KIR3DL1	2.98e-04	6	90	2	GO:0030109
HumanPheno	Typified by somatic mosaicism	TET2 MSH6 ERBB2 EGFR TSC2 ASPSCR1 RAD54L AXIN2	6.34e-06	168	32	8	HP:0001442
HumanPheno	Somatic mutation	TET2 MSH6 ERBB2 EGFR TSC2 ASPSCR1 RAD54L AXIN2	6.34e-06	168	32	8	HP:0001428
Domain	Tyr_kinase_EGF/ERB/XmrK_rcpt	ERBB2 EGFR	1.34e-04	4	89	2	IPR016245
Domain	GF_recep_IV	ERBB2 EGFR	3.33e-04	6	89	2	PF14843
Domain	GF_recep_IV	ERBB2 EGFR	3.33e-04	6	89	2	IPR032778
Domain	Furin-like	ERBB2 EGFR	4.64e-04	7	89	2	PF00757
Domain	Rcpt_L-dom	ERBB2 EGFR	4.64e-04	7	89	2	IPR000494
Domain	Furin-like_Cys-rich_dom	ERBB2 EGFR	4.64e-04	7	89	2	IPR006211
Domain	Recep_L_domain	ERBB2 EGFR	4.64e-04	7	89	2	PF01030
Domain	-	ERBB2 EGFR	4.64e-04	7	89	2	3.80.20.20
Domain	Ig-like_fold	MXRA5 LILRB2 VCAN KIR3DL3 KIR3DL1 KIR3DS1 USH2A TAPBP HCFC1 LEPR LILRA4	5.21e-04	706	89	11	IPR013783
Domain	LAM_G_DOMAIN	FAT4 FAT3 USH2A	7.82e-04	38	89	3	PS50025
Domain	Laminin_G_2	FAT4 FAT3 USH2A	9.10e-04	40	89	3	PF02210
Domain	LamG	FAT4 FAT3 USH2A	1.20e-03	44	89	3	SM00282
Domain	Ubiquitin-rel_dom	RASSF6 UHRF1 DGKQ ASPSCR1 AXIN2	1.87e-03	184	89	5	IPR029071
Domain	IG_LIKE	MXRA5 LILRB2 VCAN KIR3DL3 KIR3DL1 TAPBP LEPR LILRA4	2.36e-03	491	89	8	PS50835
Domain	Sulfatase_CS	ARSH ARSA	2.58e-03	16	89	2	IPR024607
Domain	Laminin_G	FAT4 FAT3 USH2A	2.67e-03	58	89	3	IPR001791
Domain	Ig-like_dom	MXRA5 LILRB2 VCAN KIR3DL1 KIR3DS1 TAPBP LEPR LILRA4	2.74e-03	503	89	8	IPR007110
Domain	SULFATASE_1	ARSH ARSA	2.91e-03	17	89	2	PS00523
Domain	SULFATASE_2	ARSH ARSA	2.91e-03	17	89	2	PS00149
Domain	Sulfatase	ARSH ARSA	3.27e-03	18	89	2	PF00884
Domain	Furin_repeat	ERBB2 EGFR	3.27e-03	18	89	2	IPR006212
Domain	Sulfatase_N	ARSH ARSA	3.27e-03	18	89	2	IPR000917
Domain	FU	ERBB2 EGFR	3.27e-03	18	89	2	SM00261
Domain	IG	MXRA5 LILRB2 VCAN KIR3DL3 KIR3DL1 KIR3DS1 LILRA4	3.97e-03	421	89	7	SM00409
Domain	Ig_sub	MXRA5 LILRB2 VCAN KIR3DL3 KIR3DL1 KIR3DS1 LILRA4	3.97e-03	421	89	7	IPR003599
Domain	-	MXRA5 VCAN KIR3DL1 KIR3DS1 USH2A TAPBP HCFC1 LEPR LILRA4	4.30e-03	663	89	9	2.60.40.10
Pathway	WP_GLIOBLASTOMA_SIGNALING	MSH6 ERBB2 EGFR E2F1 TSC2	3.92e-05	83	65	5	M39637
Pubmed	HER2/EGFR-AKT Signaling Switches TGFβ from Inhibiting Cell Proliferation to Promoting Cell Migration in Breast Cancer.	ERBB2 EGFR SMAD3	6.92e-08	4	91	3	30171053
Pubmed	HLA-F and MHC-I Open Conformers Bind Natural Killer Cell Ig-Like Receptor KIR3DS1.	LILRB2 KIR3DL1 KIR3DS1	9.61e-07	8	91	3	27649529
Pubmed	Different patterns of evolution in the centromeric and telomeric regions of group A and B haplotypes of the human killer cell Ig-like receptor locus.	KIR3DL3 KIR3DL1 KIR3DS1	2.05e-06	10	91	3	21206914
Pubmed	[Polymorphism of killer cell immunoglobulin-like receptor gene and its correlation with leukemia].	KIR3DL3 KIR3DL1 KIR3DS1	3.75e-06	12	91	3	17490516
Pubmed	A dual-activity topoisomerase complex regulates mRNA translation and turnover.	CCDC142 ERBB2 TBC1D9B NDOR1 CTC1 MAEA DGKQ ZFYVE26 TSC2 RHOT2 ATG2A HCFC1 IQGAP3	6.06e-06	1105	91	13	35748872
Pubmed	Frequencies of killer immunoglobulin-like receptor genotypes influence susceptibility to spontaneous abortion.	KIR3DL3 KIR3DL1 KIR3DS1	6.18e-06	14	91	3	19875891
Pubmed	Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia.	KIR3DL3 KIR3DL1 KIR3DS1	6.18e-06	14	91	3	18945962
Pubmed	[Genotype and haplotype analysis of killer cell immunoglobulin-like receptors in ankylosing spondylitis].	KIR3DL3 KIR3DL1 KIR3DS1	6.18e-06	14	91	3	19489269
Pubmed	Distribution of killer cell immunoglobulin-like receptor genes in the Chinese Han population.	KIR3DL3 KIR3DL1 KIR3DS1	6.18e-06	14	91	3	15896204
Pubmed	Systematic bromodomain protein screens identify homologous recombination and R-loop suppression pathways involved in genome integrity.	ARG2 AMBN MSH6 ERBB2 ARHGEF33 FAT3 RHOT2 ADGRL2 IQCM PDZRN3 SIRT1 AGTPBP1 ZNF574	6.74e-06	1116	91	13	31753913
Pubmed	Elevated epidermal growth factor receptor phosphorylation induces resistance artery dysfunction in diabetic db/db mice.	EGFR LEPR	6.77e-06	2	91	2	18319304
Pubmed	Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer.	ERBB2 EGFR	6.77e-06	2	91	2	25349977
Pubmed	Prognostic role of human epidermal growth factor receptor in gastric cancer: a systematic review and meta-analysis.	ERBB2 EGFR	6.77e-06	2	91	2	23871709
Pubmed	HER1 R497K and HER2 I655V polymorphisms are linked to development of breast cancer.	ERBB2 EGFR	6.77e-06	2	91	2	23594562
Pubmed	Identification of autophosphorylation sites of HER2/neu.	ERBB2 EGFR	6.77e-06	2	91	2	1706616
Pubmed	Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells.	ERBB2 EGFR	6.77e-06	2	91	2	19946741
Pubmed	EGFR and ERBB2 Exon 20 Insertion Mutations in Chinese Non-small Cell Lung Cancer Patients: Pathological and Molecular Characterization, and First-Line Systemic Treatment Evaluation.	ERBB2 EGFR	6.77e-06	2	91	2	38416376
Pubmed	Evolutionary analysis of the ErbB receptor and ligand families.	ERBB2 EGFR	6.77e-06	2	91	2	10824084
Pubmed	Synergistic Blockade of EGFR and HER2 by New-Generation EGFR Tyrosine Kinase Inhibitor Enhances Radiation Effect in Bladder Cancer Cells.	ERBB2 EGFR	6.77e-06	2	91	2	25589492
Pubmed	Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study.	ERBB2 EGFR	6.77e-06	2	91	2	15143334
Pubmed	Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib.	ERBB2 EGFR	6.77e-06	2	91	2	18199554
Pubmed	Expression of erbB-1 and erbB-2 genes in normal and pathological human endometrium.	ERBB2 EGFR	6.77e-06	2	91	2	17549377
Pubmed	The efficient elimination of solid tumor cells by EGFR-specific and HER2-specific scFv-SNAP fusion proteins conjugated to benzylguanine-modified auristatin F.	ERBB2 EGFR	6.77e-06	2	91	2	27502168
Pubmed	Frequent genetic alterations in EGFR- and HER2-driven pathways in breast cancer brain metastases.	ERBB2 EGFR	6.77e-06	2	91	2	23665199
Pubmed	Epidermal growth factor receptor activity is necessary for mouse basal cell proliferation.	ERBB2 EGFR	6.77e-06	2	91	2	25217659
Pubmed	EGFR and HER2 expression in advanced biliary tract cancer.	ERBB2 EGFR	6.77e-06	2	91	2	19777609
Pubmed	Versican G3 promotes mouse mammary tumor cell growth, migration, and metastasis by influencing EGF receptor signaling.	EGFR VCAN	6.77e-06	2	91	2	21079779
Pubmed	Increased concentrations of growth factors and activation of the EGFR system in breast cancer.	ERBB2 EGFR	6.77e-06	2	91	2	23089711
Pubmed	EGFR Expression in HER2-Driven Breast Cancer Cells.	ERBB2 EGFR	6.77e-06	2	91	2	33260837
Pubmed	The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma.	ERBB2 EGFR	6.77e-06	2	91	2	34487971
Pubmed	Screening and validation of dinucleotide repeats in intron 1 of the human EGFR gene and its paralog in the HER2 gene.	ERBB2 EGFR	6.77e-06	2	91	2	18946768
Pubmed	Design, biological evaluation and 3D QSAR studies of novel dioxin-containing pyrazoline derivatives with thiourea skeleton as selective HER-2 inhibitors.	ERBB2 EGFR	6.77e-06	2	91	2	27273260
Pubmed	Induction of cancer cell migration by epidermal growth factor is initiated by specific phosphorylation of tyrosine 1248 of c-erbB-2 receptor via EGFR.	ERBB2 EGFR	6.77e-06	2	91	2	12354693
Pubmed	Fluorescence-Raman dual modal endoscopic system for multiplexed molecular diagnostics.	ERBB2 EGFR	6.77e-06	2	91	2	25820115
Pubmed	Expression of EGFR, Her2 predict lymph node metastasis (LNM)-associated metastasis in colorectal cancer.	ERBB2 EGFR	6.77e-06	2	91	2	23220854
Pubmed	Gangliosides influence EGFR/ErbB2 heterodimer stability but they do not modify EGF-dependent ErbB2 phosphorylation.	ERBB2 EGFR	6.77e-06	2	91	2	20156584
Pubmed	EGFR and HER-2 oncogenes expression in an experimental model of two-stage chemically induced carcinogenesis in mouse skin.	ERBB2 EGFR	6.77e-06	2	91	2	38443188
Pubmed	Differential spatial expression and activation pattern of EGFR and HER2 in human breast cancer.	ERBB2 EGFR	6.77e-06	2	91	2	17611648
Pubmed	Protective genotypes in HIV infection reflect superior function of KIR3DS1+ over KIR3DL1+ CD8+ T cells.	KIR3DL1 KIR3DS1	6.77e-06	2	91	2	25112829
Pubmed	Unusual selection on the KIR3DL1/S1 natural killer cell receptor in Africans.	KIR3DL1 KIR3DS1	6.77e-06	2	91	2	17694054
Pubmed	A novel dual EGFR/HER2 inhibitor KU004 induces cell cycle arrest and apoptosis in HER2-overexpressing cancer cells.	ERBB2 EGFR	6.77e-06	2	91	2	26437915
Pubmed	EGFR and HER2 receptor kinase signaling mediate epithelial cell invasion by Candida albicans during oropharyngeal infection.	ERBB2 EGFR	6.77e-06	2	91	2	22891338
Pubmed	Anti-EGFR antibody efficiently and specifically inhibits human TSC2-/- smooth muscle cell proliferation. Possible treatment options for TSC and LAM.	EGFR TSC2	6.77e-06	2	91	2	18958173
Pubmed	Expression of epidermal growth factor receptor and HER-2 in pediatric embryonal brain tumors.	ERBB2 EGFR	6.77e-06	2	91	2	20962551
Pubmed	Structural and energetic basis for the molecular recognition of dual synthetic vs. natural inhibitors of EGFR/HER2.	ERBB2 EGFR	6.77e-06	2	91	2	29329808
Pubmed	Undetectable histone O-GlcNAcylation in mammalian cells.	TET2 HCFC1	6.77e-06	2	91	2	26075789
Pubmed	Identification of E2F1 as an important transcription factor for the regulation of tapasin expression.	E2F1 TAPBP	6.77e-06	2	91	2	20663889
Pubmed	Dual-Receptor-Targeted (DRT) Radiation Nanomedicine Labeled with 177Lu Is More Potent for Killing Human Breast Cancer Cells That Coexpress HER2 and EGFR Than Single-Receptor-Targeted (SRT) Radiation Nanomedicines.	ERBB2 EGFR	6.77e-06	2	91	2	32022567
Pubmed	Comparative analysis of fluorescence resonance energy transfer (FRET) and proximity ligation assay (PLA).	ERBB2 EGFR	6.77e-06	2	91	2	21480528
Pubmed	Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas.	ERBB2 EGFR	6.77e-06	2	91	2	21087480
Pubmed	A Comparison of Immunohistochemical Expression of Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2 in Dental Follicles with Different Radiographic Sizes.	ERBB2 EGFR	6.77e-06	2	91	2	39205824
Pubmed	Lapatinib, a dual inhibitor of ErbB-1/-2 receptors, enhances effects of combination chemotherapy in bladder cancer cells.	ERBB2 EGFR	6.77e-06	2	91	2	19287975
Pubmed	The signaling and transformation potency of the overexpressed HER2 protein is dependent on the normally-expressed EGFR.	ERBB2 EGFR	6.77e-06	2	91	2	21911055
Pubmed	Identification of Smad3-related transcriptomes in type-2 diabetic nephropathy by whole transcriptome RNA sequencing.	LEPR SMAD3	6.77e-06	2	91	2	33369170
Pubmed	Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells.	ERBB2 EGFR	6.77e-06	2	91	2	12586780
Pubmed	Overexpression of Epidermal Growth Factor Receptor (EGFR) and HER-2 in Bladder Carcinoma and Its Association with Patients' Clinical Features.	ERBB2 EGFR	6.77e-06	2	91	2	30296252
Pubmed	EGFR and ERBB2 Germline Mutations in Chinese Lung Cancer Patients and Their Roles in Genetic Susceptibility to Cancer.	ERBB2 EGFR	6.77e-06	2	91	2	30610926
Pubmed	E2F1 contributes to the transcriptional activation of the KIR3DL1 gene.	E2F1 KIR3DL1	6.77e-06	2	91	2	18358829
Pubmed	A method for killer-cell immunoglobulin-like receptor (KIR) 3DL1/3DS1 genotyping using DNA recovered from frozen plasma.	KIR3DL1 KIR3DS1	6.77e-06	2	91	2	23524032
Pubmed	EGFR negates the proliferative effect of oncogenic HER2 in MDA-MB-231 cells.	ERBB2 EGFR	6.77e-06	2	91	2	25935365
Pubmed	Deletion of Smad3 protects against diabetic myocardiopathy in db/db mice.	LEPR SMAD3	6.77e-06	2	91	2	33733577
Pubmed	Serum levels of epidermal growth factor and HER-2 neu in non small-cell lung cancer: prognostic correlation.	ERBB2 EGFR	6.77e-06	2	91	2	19093231
Pubmed	SIRT1 Activation Disrupts Maintenance of Myelodysplastic Syndrome Stem and Progenitor Cells by Restoring TET2 Function.	TET2 SIRT1	6.77e-06	2	91	2	30146412
Pubmed	Circular HER2 RNA positive triple negative breast cancer is sensitive to Pertuzumab.	ERBB2 EGFR	6.77e-06	2	91	2	32917240
Pubmed	EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapy.	ERBB2 EGFR	6.77e-06	2	91	2	18650488
Pubmed	Genomic activation of the EGFR and HER2-neu genes in a significant proportion of invasive epithelial ovarian cancers.	ERBB2 EGFR	6.77e-06	2	91	2	18182111
Pubmed	Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients.	ERBB2 EGFR	6.77e-06	2	91	2	17626639
Pubmed	Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice.	ERBB2 EGFR	6.77e-06	2	91	2	26330166
Pubmed	Smad3 Mediates Diabetic Dyslipidemia and Fatty Liver in db/db Mice by Targeting PPARδ.	LEPR SMAD3	6.77e-06	2	91	2	37511155
Pubmed	The Transmodulation of HER2 and EGFR by Substance P in Breast Cancer Cells Requires c-Src and Metalloproteinase Activation.	ERBB2 EGFR	6.77e-06	2	91	2	26114632
Pubmed	Assessment of HER1 (rs11543848) and HER2 (rs1136201) polymorphism and their association with colorectal cancer susceptibility in Khyber Pakhtunkhwa, Pakistan.	ERBB2 EGFR	6.77e-06	2	91	2	38040921
Pubmed	HER2 and EGFR amplification and expression in urothelial carcinoma occurs in distinct biological and molecular contexts.	ERBB2 EGFR	6.77e-06	2	91	2	28388586
Pubmed	EGFR and erbB2 mutation status in Japanese lung cancer patients.	ERBB2 EGFR	6.77e-06	2	91	2	16003726
Pubmed	Asp746 to glycine change may have a greater influence than Cys751 to serine change in accounting for ligand selectivity between EGFR and HER-2 at the ATP site.	ERBB2 EGFR	6.77e-06	2	91	2	16184431
Pubmed	Direct and immune mediated antibody targeting of ERBB receptors in a colorectal cancer cell-line panel.	ERBB2 EGFR	6.77e-06	2	91	2	23213241
Pubmed	Ganglioside GM(3) is stably associated to tyrosine-phosphorylated ErbB2/EGFR receptor complexes and EGFR monomers, but not to ErbB2.	ERBB2 EGFR	6.77e-06	2	91	2	17521961
Pubmed	Distribution of prognostically unfavourable product of c-erbB-2 oncogene and EGF-R in carcinomas of the breast and uterine cervix.	ERBB2 EGFR	6.77e-06	2	91	2	12683217
Pubmed	MiR-138 promotes smooth muscle cells proliferation and migration in db/db mice through down-regulation of SIRT1.	LEPR SIRT1	6.77e-06	2	91	2	26079878
Pubmed	HLA class I subtype-dependent expansion of KIR3DS1+ and KIR3DL1+ NK cells during acute human immunodeficiency virus type 1 infection.	KIR3DL1 KIR3DS1	6.77e-06	2	91	2	19386717
Pubmed	Parsing ERK activation reveals quantitatively equivalent contributions from epidermal growth factor receptor and HER2 in human mammary epithelial cells.	ERBB2 EGFR	6.77e-06	2	91	2	15572377
Pubmed	EGFR and HER2 exert distinct roles on colon cancer cell functional properties and expression of matrix macromolecules.	ERBB2 EGFR	6.77e-06	2	91	2	24792576
Pubmed	ErbB1 and ErbB2 overexpression in patients with sinonasal inverted papilloma and inverted papilloma with squamous cell carcinoma in China.	ERBB2 EGFR	6.77e-06	2	91	2	31556771
Pubmed	Putative role of KIR3DL1/3DS1 alleles and HLA-Bw4 ligands with end stage renal disease and long term renal allograft survival.	KIR3DL1 KIR3DS1	6.77e-06	2	91	2	28942035
Pubmed	Characterization of EGFR and ErbB2 expression in atopic dermatitis patients.	ERBB2 EGFR	6.77e-06	2	91	2	22552355
Pubmed	Protein interactions with HER-family receptors can have different characteristics depending on the hosting cell line.	ERBB2 EGFR	6.77e-06	2	91	2	22200885
Pubmed	Effects of gefitinib on serum epidermal growth factor receptor and HER2 in patients with advanced non-small cell lung cancer.	ERBB2 EGFR	6.77e-06	2	91	2	15447984
Pubmed	Development of a PCR-SSOP approach capable of defining the natural killer cell inhibitory receptor (KIR) gene sequence repertoires.	KIR3DL1 KIR3DS1	6.77e-06	2	91	2	11098931
Pubmed	Tissue microarray analysis of EGFR and HER2 oncogene copy number alterations in squamous cell carcinoma of the larynx.	ERBB2 EGFR	6.77e-06	2	91	2	15592685
Pubmed	Transactivation of EGF receptor and ErbB2 protects intestinal epithelial cells from TNF-induced apoptosis.	ERBB2 EGFR	6.77e-06	2	91	2	18701712
Pubmed	ERBB2 is a target for USP8-mediated deubiquitination.	ERBB2 EGFR	6.77e-06	2	91	2	21044682
Pubmed	Urothelial cancer harbours EGFR and HER2 amplifications and exon 20 insertions.	ERBB2 EGFR	6.77e-06	2	91	2	31985116
Pubmed	Potential advantages of CUDC-101, a multitargeted HDAC, EGFR, and HER2 inhibitor, in treating drug resistance and preventing cancer cell migration and invasion.	ERBB2 EGFR	6.77e-06	2	91	2	23536719
Pubmed	A new class of protein cancer biomarker candidates: differentially expressed splice variants of ERBB2 (HER2/neu) and ERBB1 (EGFR) in breast cancer cell lines.	ERBB2 EGFR	6.77e-06	2	91	2	24802673
Pubmed	A benzimidazole derivative exhibiting antitumor activity blocks EGFR and HER2 activity and upregulates DR5 in breast cancer cells.	ERBB2 EGFR	6.77e-06	2	91	2	25766325
Pubmed	HER2 and EGFR Overexpression Support Metastatic Progression of Prostate Cancer to Bone.	ERBB2 EGFR	6.77e-06	2	91	2	27793843
Pubmed	Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer.	ERBB2 EGFR	6.77e-06	2	91	2	14734462
Pubmed	Moderate SIRT1 overexpression protects against brown adipose tissue inflammation.	LEPR SIRT1	6.77e-06	2	91	2	33049408
Pubmed	SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function.	NDOR1 SIRT1	6.77e-06	2	91	2	22560220
Pubmed	Establishment and characterization of a novel ovarian serous adenocarcinoma cell line, TU-OS-4, that overexpresses EGFR and HER2.	ERBB2 EGFR	6.77e-06	2	91	2	23274876
Pubmed	Immunohistochemical based molecular subtypes of muscle-invasive bladder cancer: association with HER2 and EGFR alterations, neoadjuvant chemotherapy response and survival.	ERBB2 EGFR	6.77e-06	2	91	2	36737799
Cytoband	19q13.4	LILRB2 KIR3DL1 KIR3DS1 LILRA4	1.94e-05	79	91	4	19q13.4
Cytoband	2p22.1	ARHGEF33 GALM	4.58e-04	16	91	2	2p22.1
Cytoband	1p31	RPE65 LEPR	7.96e-04	21	91	2	1p31
Cytoband	Xp22.33	ARSH MXRA5	1.13e-03	25	91	2	Xp22.33
Cytoband	10q21.3	PBLD SIRT1	2.09e-03	34	91	2	10q21.3
Cytoband	14q24.1	ARG2 ZFYVE26	2.22e-03	35	91	2	14q24.1
Cytoband	22q13.33	ARSA PPP6R2	2.61e-03	38	91	2	22q13.33
Cytoband	4q13.3	ADAMTS3 RASSF6	3.18e-03	42	91	2	4q13.3
Cytoband	Ensembl 112 genes in cytogenetic band chr4q13	AMBN ADAMTS3 RASSF6	3.82e-03	157	91	3	chr4q13
GeneFamily	CD molecules\|Killer cell immunoglobulin like receptors	KIR3DL3 KIR3DL1 KIR3DS1	2.47e-05	18	58	3	620
GeneFamily	Erb-b2 receptor tyrosine kinases	ERBB2 EGFR	6.04e-05	4	58	2	1096
GeneFamily	Cadherin related	FAT4 FAT3	1.33e-03	17	58	2	24
GeneFamily	Sulfatases	ARSH ARSA	1.50e-03	18	58	2	410
GeneFamily	ADAM metallopeptidase domain containing\|CD molecules	ERBB2 LILRB2 KIR3DL3 KIR3DL1 LEPR LILRA4	1.60e-03	394	58	6	471
GeneFamily	G-patch domain containing\|Minor histocompatibility antigens	CHERP GPATCH8	2.24e-03	22	58	2	579
GeneFamily	Autophagy related	ATG4B ATG2A	5.01e-03	33	58	2	1022
Coexpression	HE_LIM_SUN_FETAL_LUNG_C1_EARLY_TIP_CELL	ARG2 VCAN UHRF1 E2F1 RFX6 RAD54L	1.10e-05	145	90	6	M45693
Coexpression	BREUHAHN_GROWTH_FACTOR_SIGNALING_IN_LIVER_CANCER	ERBB2 EGFR AXIN2	1.73e-05	15	90	3	M18219
Coexpression	GOBERT_OLIGODENDROCYTE_DIFFERENTIATION_UP	MSH6 CTC1 VCAN UHRF1 E2F1 RHOT2 ADGRL2 IQGAP3 PDZRN3 RAD54L	2.96e-05	578	90	10	M2368
ToppCell	PCW_10-12-Mesenchymal-Mesenchymal_fibroblastic-mes_immature1_(0)\|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung	FAT4 MAST4 ASXL3 FAT3 VCAN ADGRL2 PDZRN3	1.52e-07	197	90	7	11a4c417f035e554431a8f03be13b5eefa3530c0
ToppCell	Striatum-Endothelial-MURAL-M1(Rgs5Acta2)-M1_3-MURAL_Mural.Rgs5Acta2.Col3a1_(Mural.Rgs5Acta2.Col3a1)-\|Striatum / BrainAtlas - Mouse McCarroll V32	TRABD2B GALM MICALL2 RASSF6 CDC42EP5 LEPR	3.16e-07	134	90	6	a3547a68012d879d4dfe80394eace70808722e43
ToppCell	Striatum-Endothelial-MURAL-M1(Rgs5Acta2)-M1_3-MURAL_Mural.Rgs5Acta2.Col3a1_(Mural.Rgs5Acta2.Col3a1)\|Striatum / BrainAtlas - Mouse McCarroll V32	TRABD2B GALM MICALL2 RASSF6 CDC42EP5 LEPR	3.16e-07	134	90	6	9458e2d0dbc18d9025b66b59f3ecc2fbc5384940
ToppCell	5'-Adult-LargeIntestine-Mesenchymal-fibroblastic-Stromal_1_(ADAMDEC1+)\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	FAT4 MXRA5 RTL1 VCAN ADGRL2 PDZRN3	1.23e-06	169	90	6	c0824a93674e2bff0f09b2d2fab5bab016a2e379
ToppCell	10x5'v1-week_12-13-Mesenchymal_adipo-stroma\|week_12-13 / cell types per 3 fetal stages;per 3',per 5'	FAT4 TRABD2B MXRA5 EGFR ASXL3 LEPR	2.66e-06	193	90	6	cf2461af78f65616ce40d552ee9452295e3895ed
ToppCell	10x5'v1-week_12-13-Mesenchymal_adipo\|week_12-13 / cell types per 3 fetal stages;per 3',per 5'	FAT4 TRABD2B MXRA5 EGFR ASXL3 LEPR	2.66e-06	193	90	6	6ef9007c9d18fb775d08fb20cdf954a28d54d7eb
ToppCell	10x5'v1-week_12-13-Mesenchymal_adipo-stroma-adipo-CAR\|week_12-13 / cell types per 3 fetal stages;per 3',per 5'	FAT4 TRABD2B MXRA5 EGFR ASXL3 LEPR	2.66e-06	193	90	6	e4ea7ce011a80b81b841c907719aa532bed39d2e
ToppCell	Bronchial-NucSeq-Epithelial-Epi_airway_neuro-secretory\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	LRGUK RUNDC3A RASSF6 ASXL3 FAT3 RFX6	2.74e-06	194	90	6	2dcc3b99dbedaf8a6916891c85091ddb79d7ee31
ToppCell	PCW_10-12-Mesenchymal-Mesenchymal_fibroblastic\|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung	FAT4 MAST4 FAT3 VCAN CDC42EP5 PDZRN3	3.08e-06	198	90	6	17dc055e2a289496d9c5cdbf3297bdf906dc6d22
ToppCell	10x3'2.3-week_17-19-Mesenchymal_fibro-stroma-arteriolar_fibroblast\|week_17-19 / cell types per 3 fetal stages;per 3',per 5'	FAT4 TRABD2B MXRA5 EGFR CDC42EP5 PDZRN3	3.17e-06	199	90	6	95d95e9b7bd3933188998ae94986213eb0f1e5ea
ToppCell	LPS_anti-TNF-Endothelial-Endothelial-FOXM1\|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type	UHRF1 CDK5RAP2 E2F1 RPE65 IQGAP3 RAD54L	3.17e-06	199	90	6	98575fcce726589e93fbb4df1aab03e57cb56076
ToppCell	Bronchial-NucSeq-Stromal-Fibroblastic-Fibro_peribronchial\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	FAT4 MXRA5 VCAN ADGRL2 PDZRN3 LEPR	3.27e-06	200	90	6	fb53be20392a8309a7393774c774a1b1aec6e676
ToppCell	Tracheal-NucSeq-Stromal-Fibroblastic-Fibro_peribronchial\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	FAT4 AHRR MXRA5 VCAN PDZRN3 LEPR	3.27e-06	200	90	6	58b38f9a484ee94191091a0659ed62ebed2d4a14
ToppCell	renal_cortex_nuclei-Hypertensive_with+without-CKD-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell_cycling-Cycling_Proximal_Tubule_Epithelial_Cell_S-high\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	AMBN UHRF1 E2F1 IQGAP3 RAD54L	2.13e-05	165	90	5	88681101d7cf60b99b8ace5d8c0944323b937306
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell-Cycling_Myofibroblast-\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	VCAN UHRF1 E2F1 IQGAP3 RAD54L	2.53e-05	171	90	5	b0373ed8283ee1792b6a490bff93906546978593
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell-Cycling_Myofibroblast\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	VCAN UHRF1 E2F1 IQGAP3 RAD54L	2.53e-05	171	90	5	b92963f9f247d2e5e2e6c51c6dbf70e527cd2f55
ToppCell	renal_cortex_nuclei-Hypertensive_with+without-CKD-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell_cycling\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	AMBN UHRF1 E2F1 IQGAP3 RAD54L	2.68e-05	173	90	5	a25459b8140b0dbcb73e3b4cc1407b679229f25c
ToppCell	ASK428-Immune-B_cell\|Immune / Donor, Lineage and Cell class of Lung cells from Dropseq	MSH6 ERBB2 MAEA LEPR ERMN	2.83e-05	175	90	5	e0979e5795a49b4e5c9b88e7fe6b7bda7a413a6c
ToppCell	renal_medulla_nuclei-Adult_normal_reference-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_descending_limb_epithelial_cell-Descending_Thin_Limb_Cell_Type_2\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	ADAMTS3 EGFR FAT3 PDZRN3 SMAD3	3.32e-05	181	90	5	6956ecd6264f7469a25e555673bce4eb97d28f7a
ToppCell	pdx\|World / Sample and Cell Type and Tumor Cluster (all cells)	CCDC170 RHBG ASPSCR1 GPATCH8 PPP6R2	3.78e-05	186	90	5	de8e538c8767d41b8a52f5e58ba1affd4e7244c4
ToppCell	pdx-Tumor_cells\|World / Sample and Cell Type and Tumor Cluster (all cells)	CCDC170 RHBG ASPSCR1 GPATCH8 PPP6R2	3.78e-05	186	90	5	0b88a87158a9ca8de3bf40a4ff1687150707a5f0
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell_cycling\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	UHRF1 CDK5RAP2 E2F1 IQGAP3 RAD54L	3.88e-05	187	90	5	9351fa87b69a951af85b10bf91fe9b1cce8c0517
ToppCell	Control-Fibroblasts-Other_FB\|Control / group, cell type (main and fine annotations)	FAT4 FAT3 ADGRL2 PDZRN3 LEPR	3.88e-05	187	90	5	bd3739c4a52aa1ba5deffd778e113a9800f7e158
ToppCell	Control-Myeloid-cMonocyte\|Myeloid / Disease state, Lineage and Cell class	TET2 LILRB2 VCAN AGTPBP1 SMAD3	3.98e-05	188	90	5	47126c371a242c937499fd278a74a882df8f759c
ToppCell	COPD-Myeloid-cMonocyte\|Myeloid / Disease state, Lineage and Cell class	TET2 LILRB2 VCAN AGTPBP1 SMAD3	4.08e-05	189	90	5	6294691231c7d38707323cf31578a107d3b2c622
ToppCell	IPF-Myeloid-cMonocyte\|Myeloid / Disease state, Lineage and Cell class	TET2 LILRB2 VCAN AGTPBP1 SMAD3	4.08e-05	189	90	5	ad7bb3a7de8e48c145e4382f90d30bb2159c2b76
ToppCell	droplet-Lung-21m-Hematologic-lymphocytic-Proliferating_T_cell-proliferating_T\|21m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	ARHGEF33 UHRF1 IQGAP3 RAD54L ERMN	4.29e-05	191	90	5	15dbc5a03bfab8931c0fd385b0f25874736ae874
ToppCell	droplet-Lung-21m-Hematologic-lymphocytic-Proliferating_T_cell\|21m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	ARHGEF33 UHRF1 IQGAP3 RAD54L ERMN	4.29e-05	191	90	5	45c15f5ce4a207ac944bed65d45f06c1657d1a6d
ToppCell	3'-Distal_airway-Immune_Myeloid-Myeloid_macrophage-alveolar_macrophage-Alveolar_macrophage_proliferating-Alveolar_macrophage_proliferating_L.1.0.7.0\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	UHRF1 E2F1 IQGAP3 RAD54L LILRA4	4.29e-05	191	90	5	b85a0978dc1e8af4f49423f56dcfd52efce09ed1
ToppCell	Control-Myeloid-cMonocyte\|Control / Disease state, Lineage and Cell class	TET2 LILRB2 VCAN AGTPBP1 SMAD3	4.40e-05	192	90	5	ad04c9c4bdebf94615cee1904ca48197e62c923b
ToppCell	Children_(3_yrs)-Immune-monocyte-D046\|Children_(3_yrs) / Lineage, Cell type, age group and donor	TET2 LILRB2 VCAN SKAP2 AGTPBP1	4.51e-05	193	90	5	58e1930a1d80ad3729ab9604ac8ebf7308232a3d
ToppCell	LPS-IL1RA+antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ADAMTS3 ASXL3 FAT3 PDZRN3 CDH10	4.51e-05	193	90	5	fb28717fadd06c3840636d25409ce80c9254bd34
ToppCell	Control-Myeloid-cMonocyte\|World / Disease state, Lineage and Cell class	TET2 LILRB2 VCAN AGTPBP1 SMAD3	4.62e-05	194	90	5	f852f5258617a66a4fbd56d64c7b47272e7b8b60
ToppCell	PCW_13-14-Mesenchymal-Mesenchymal_fibroblastic-mes_immature5_(6)\|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung	FAT4 EGFR FAT3 VCAN ADGRL2	4.62e-05	194	90	5	b1bb0f846d2865efdd9bc8842b16b9d069785882
ToppCell	LV-14._Fibroblast_III\|LV / Chamber and Cluster_Paper	TRABD2B EGFR VCAN LEPR SMAD3	4.62e-05	194	90	5	927c26aea0147f7a4b8fb3f192de4de263f1b978
ToppCell	kidney_cells-Renal_AKI_(acute_kidney_injury)-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell_cycling-Cycling_Proximal_Tubule_Epithelial_Cell_S-high\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	MSH6 UHRF1 E2F1 IQGAP3 RAD54L	4.62e-05	194	90	5	4c1d13d8cb6fb424655c67755ee6dbaf59d6b418
ToppCell	PCW_10-12-Mesenchymal-Mesenchymal_fibroblastic-mes_immature3_(17)\|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung	FAT4 MAST4 FAT3 VCAN ADGRL2	4.74e-05	195	90	5	1cdf5f296029ae424d9dba42e86a6d111e4896e6
ToppCell	PCW_10-12-Mesenchymal-Mesenchymal_fibroblastic-mes_immature5_(6)\|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung	FAT4 EGFR FAT3 VCAN ADGRL2	4.74e-05	195	90	5	0e55fa5b3cbeb7baee3d4ac272a3bf80381ec937
ToppCell	PCW_13-14-Mesenchymal-Mesenchymal_fibroblastic\|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung	FAT4 MAST4 FAT3 VCAN PDZRN3	4.85e-05	196	90	5	1450cb69c5bf469e97c03bf1890f6f7c54165b8a
ToppCell	10x3'2.3-week_17-19-Mesenchymal_adipo\|week_17-19 / cell types per 3 fetal stages;per 3',per 5'	TRABD2B MXRA5 EGFR VCAN LEPR	4.97e-05	197	90	5	5afddde4e2b5cd55abe11e9b9efae02dbdc3da3a
ToppCell	10x3'2.3-week_17-19-Mesenchymal_adipo-stroma-adipo-CAR\|week_17-19 / cell types per 3 fetal stages;per 3',per 5'	TRABD2B MXRA5 EGFR VCAN LEPR	4.97e-05	197	90	5	1baffd087ca194a7355fefbb3bf67befb14fe2de
ToppCell	10x3'2.3-week_17-19-Mesenchymal_adipo-stroma\|week_17-19 / cell types per 3 fetal stages;per 3',per 5'	TRABD2B MXRA5 EGFR VCAN LEPR	4.97e-05	197	90	5	b9745e382baa2725dfcae060701fb53f6c8a31fa
ToppCell	PCW_13-14-Mesenchymal-Mesenchymal_fibroblastic-mes_immature1_(0)\|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung	MAST4 ASXL3 FAT3 VCAN ADGRL2	4.97e-05	197	90	5	0034bae02ee7fcfea520d453ca3c842ab6963b12
ToppCell	distal-Hematologic-Proliferating_Macrophage-2\|distal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	UHRF1 E2F1 IQGAP3 RAD54L LILRA4	5.09e-05	198	90	5	8afeb1f9bc9d8551482c8fefe4c5f88d9cd13ee2
ToppCell	stromal_cell\|World / Lineage and Cell class	TRABD2B MXRA5 EGFR ADGRL2 LEPR	5.22e-05	199	90	5	507a82d0529b5b1fa5aebcfe43db53f0b6e3f8f0
ToppCell	stromal_cell-stromal_cell\|World / Lineage and Cell class	TRABD2B MXRA5 EGFR ADGRL2 LEPR	5.22e-05	199	90	5	74262363a34da3a1eb55ab375fd61ddd7bb39b23
ToppCell	Fetal_29-31_weeks\|World / Lineage, Cell type, age group and donor	FAT4 ASXL3 FAT3 ADGRL2 PDZRN3	5.22e-05	199	90	5	5b9d355795dd03a22f0961dfd143425c367a4654
ToppCell	LPS_IL1RA-Endothelial-Endothelial-FOXM1\|LPS_IL1RA / Treatment groups by lineage, cell group, cell type	UHRF1 E2F1 RPE65 IQGAP3 RAD54L	5.22e-05	199	90	5	be2276c9a1994579ba1d2998b49bf549c1324d44
ToppCell	LPS_anti-TNF-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB\|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type	MICALL2 ADAMTS3 VCAN PDZRN3 CDH10	5.34e-05	200	90	5	9b0916d8d07ac2bf1739f7be5296bf77ffee6094
ToppCell	Control_saline-Endothelial-Endothelial-FOXM1\|Control_saline / Treatment groups by lineage, cell group, cell type	UHRF1 CDK5RAP2 E2F1 IQGAP3 RAD54L	5.34e-05	200	90	5	9bbc7b5561151f6ff65f40b3226271def732e5d9
ToppCell	Tracheal-NucSeq-Stromal\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	FAT4 TRABD2B VCAN PDZRN3 LEPR	5.34e-05	200	90	5	c318d14bd6fd6f42c597eb55ac9e2f48008aeb9b
ToppCell	Parenchymal-NucSeq-Stromal-Fibroblastic-Fibro_adventitial\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	TRABD2B ADAMTS3 VCAN PDZRN3 LEPR	5.34e-05	200	90	5	74e74123ea7bf38d337a3a0248a6a51437c6ab42
ToppCell	LPS_only-Endothelial-Endothelial-FOXM1\|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	UHRF1 SDR42E1 RPE65 IQGAP3	1.58e-04	134	90	4	4d8f7ddad02fe76a614771e115ebb8e04623ba85
ToppCell	TCGA-Brain-Primary_Tumor-Low_Grade_Glioma-Oligodendroglioma-3\|TCGA-Brain / Sample_Type by Project: Shred V9	TET2 ASXL3 VCAN SMAD3	1.62e-04	135	90	4	b128596653a5e3b64ed7f657bbfeda35438e2e48
ToppCell	facs-Marrow-B-cells-24m-Myeloid-granulocyte\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ARG2 TPH2 RPE65 FBXO15	1.81e-04	139	90	4	27dd36f5ef03fa97f0fdb19fbd259cb60e7962b3
ToppCell	facs-Marrow-B-cells-24m-Myeloid-granulocyte\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ARG2 TPH2 RPE65 FBXO15	1.81e-04	139	90	4	2a54627947f8c6597c041f4785f8a4e52d0edfba
ToppCell	LPS-antiTNF-Myeloid-Myeloid_granulocytic\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	RUNDC3A VCAN FBXO15 AGTPBP1	2.02e-04	143	90	4	4a0f26eef935fe68a1da5d319503059a8a8682dd
ToppCell	LPS-antiTNF-Myeloid-Myeloid_granulocytic-Neutrophils\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	RUNDC3A VCAN FBXO15 AGTPBP1	2.02e-04	143	90	4	65328a0a2f3972fac596e07933e74b2ef7cceb84
ToppCell	3'-Broncho-tracheal-Immune_Myeloid-Myeloid_monocytic-non-classical_monocyte-Non-classical_monocytes-\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	TET2 LILRB2 VCAN SIRT1	2.02e-04	143	90	4	7adc34d8ad11e57950a5a258ae9bf8f52259385a
ToppCell	renal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Collecting_tubule_epithelial_cell-kidney_connecting_tubule_epithelial_cell-Connecting_Tubule_Cell\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	TRABD2B TRPM5 ADAMTS3 RHBG	2.62e-04	153	90	4	9b6675ace8a83c8d446b722301d0ec4e6840f3fc
ToppCell	Healthy_Control-Myeloid-Macrophages-FCN1_high\|Healthy_Control / Condition, Lineage, Cell class and cell subclass	RUNDC3A LILRB2 VCAN FBXO15	2.75e-04	155	90	4	cd2ccb4632713b4def3a1064599b78207e2e44c0
ToppCell	facs-Liver-Non-hepatocytes-3m-Endothelial-nan\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ASXL3 FAT3 TPH2 LEPR	2.75e-04	155	90	4	8fdda4e3657ac56188ae88ed3caf145f4d9d1567
ToppCell	TCGA-Liver-Primary_Tumor-Hepatocellular_Carcinoma-Hepatocellular_Carcinoma-7\|TCGA-Liver / Sample_Type by Project: Shred V9	CCDC170 RHBG ASPSCR1 AXIN2	3.03e-04	159	90	4	70288df54adab167c0f50675128619299077db11
ToppCell	PBMC-Severe-cDC_4\|Severe / Compartment, Disease Groups and Clusters	CCDC170 AHRR GALM ZNF574	3.10e-04	160	90	4	4dac64e58d9366c399f3d830848ccb720d400be7
ToppCell	5'-GW_trimst-2-SmallIntestine-Epithelial-Tuft-related-Tuft\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	TRPM5 RASSF6 FAT3 SKAP2	3.18e-04	161	90	4	f5df8c6a340d5026726804b103e32137f363ca40
ToppCell	LPS-antiTNF-Endothelial-Endothelial-FOXM1\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	UHRF1 RPE65 IQGAP3 RAD54L	3.33e-04	163	90	4	5285318c52aa31c9b22dc2ffff078e32e408604d
ToppCell	10x_3'_v2v3-Non-neoplastic-Myeloid-Mono-Mono_naive-D\|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	CEP104 VCAN CLUH RAD54L	3.33e-04	163	90	4	4be3158f2a0ab460cfea8080a7370922910b5da9
ToppCell	BAL-Mild-cDC_0\|Mild / Compartment, Disease Groups and Clusters	CCDC170 ARG2 ERBB2 VCAN	3.33e-04	163	90	4	7047d3ba847930f42a6d5f71e18d49f3071c6409
ToppCell	367C-Myeloid-Dendritic-cDC_proliferating_2\|367C / Donor, Lineage, Cell class and subclass (all cells)	UHRF1 E2F1 IQGAP3 RAD54L	3.41e-04	164	90	4	0662cd9d21608efacc336e0a582859f3b9a4951d
ToppCell	wk_15-18-Mesenchymal-Myofibro_&_SMC-Myofibro_3\|wk_15-18 / Celltypes from embryonic and fetal-stage human lung	FAT4 FAT3 PDZRN3 AXIN2	3.41e-04	164	90	4	583dda853cee9491dbdcb228c23d8deadc20eb08
ToppCell	renal_papilla_nuclei-Adult_normal_reference-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_descending_limb_epithelial_cell-Descending_Thin_Limb_Cell_Type_2\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	ADAMTS3 EGFR RPE65 SMAD3	3.41e-04	164	90	4	382e42701779d12a7948690b3be72d06dd75c8b4
ToppCell	droplet-Lung-21m-Hematologic-myeloid-classical_monocyte-classical_monocyte_l15\|21m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	CHERP GALM NAB2 E2F1	3.49e-04	165	90	4	94a5211072464fc24592bb107a853ce832e816fe
ToppCell	10x5'-lymph-node_spleen-Myeloid_Mac-Intermediate_macrophages\|lymph-node_spleen / Manually curated celltypes from each tissue	CCDC170 AHRR LILRB2 VCAN	3.49e-04	165	90	4	c3fa9225d2f9c9e821d4fbd2315fcc98ce1f1c55
ToppCell	3'-Pediatric_IBD-SmallIntestine-Epithelial-neuro-epithelial-L_cells_(PYY+)\|Pediatric_IBD / Celltypes from developing, pediatric, Crohn's, & adult GI tract	RUNDC3A RASSF6 RFX6 RPE65	3.57e-04	166	90	4	d96c562e1483adb4cdd817b68133f03356d7279b
ToppCell	renal_papilla_nuclei-Adult_normal_reference-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell_cycling-Cycling_Proximal_Tubule_Epithelial_Cell_G2M\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	UHRF1 E2F1 IQGAP3 RAD54L	3.57e-04	166	90	4	2642544070564debe2deb2938d2c33997bf5ef02
ToppCell	5'-GW_trimst-2-SmallIntestine-Epithelial-neuro-epithelial-K_cells_(GIP+)\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	RASSF6 TPH2 RFX6 USH2A	3.57e-04	166	90	4	afba41e15478053f11815acf568d29187de75492
ToppCell	5'-Parenchyma_lung-Epithelial-Airway_epithelium-respiratory_basal_cell-Suprabasal-Suprabasal_L.0.0.2.0\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	ARG2 RASSF6 ASXL3 IQGAP3	3.57e-04	166	90	4	7495961adcefe5c1fb288913b1a5236328a04703
ToppCell	343B-Myeloid-Macrophage-FABP4+_Macrophage_proliferating_2\|343B / Donor, Lineage, Cell class and subclass (all cells)	MICALL2 UHRF1 E2F1 IQGAP3	3.65e-04	167	90	4	7efa0081e79f22b219eac64ffcaedb2179cde299
ToppCell	343B-Myeloid-Dendritic-cDC_proliferating_2\|Myeloid / Donor, Lineage, Cell class and subclass (all cells)	MSH6 UHRF1 IQGAP3 RAD54L	3.65e-04	167	90	4	3461d14e36f09ddc6ee5549ca4797e16d3f37fcc
ToppCell	5'-Adult-SmallIntestine-Epithelial-Tuft-related-Tuft\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	TET2 TRPM5 RASSF6 FAT3	3.73e-04	168	90	4	8072d0496b7b730c4601009eaa69ec5366d26d73
ToppCell	TCGA-Lung-Primary_Tumor-Lung_Carcinoma-Lung_Squamous_Cell_Carcinoma-4\|TCGA-Lung / Sample_Type by Project: Shred V9	MXRA5 VCAN PDZRN3 LILRA4	3.73e-04	168	90	4	aefea14b8b1c1b6a05f827effd22ba15274fddc9
ToppCell	kidney_cells-Hypertensive_with+without-CKD-Endothelial-blood_vessel_endothelial_cell_of_kidney-capillary-immature_endothelial_cell-Peritubular_Capilary_Endothelial_Cell__prolif\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	CDC42EP5 UHRF1 E2F1 RAD54L	3.73e-04	168	90	4	37249f38f8f04ec5743097259de67b106ca2b02f
ToppCell	343B-Epithelial_cells-Epithelial-J_(AT1-AT2_progenitors)-\|343B / Donor, Lineage, Cell class and subclass (all cells)	UHRF1 E2F1 IQGAP3 RAD54L	3.82e-04	169	90	4	a949f547b53126a208819bade74a1ac9b2a36ea7
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell_cycling-Cycling_Proximal_Tubule_Epithelial_Cell_S-high\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	UHRF1 E2F1 IQGAP3 RAD54L	3.82e-04	169	90	4	0bc8ef341ce307b19018d4ac8de0a4d04254209d
ToppCell	343B-Epithelial_cells-Epithelial-J_(AT1-AT2_progenitors)\|343B / Donor, Lineage, Cell class and subclass (all cells)	UHRF1 E2F1 IQGAP3 RAD54L	3.82e-04	169	90	4	195d5cd60d646ac6d40a3321b2f739917e7aef14
ToppCell	5'-GW_trimst-2-SmallIntestine-Epithelial-neuro-epithelial-L_cells_(PYY+)\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	RUNDC3A RASSF6 RFX6 CDH10	3.90e-04	170	90	4	985c2d5962100fab0d95bee39f382ccbe799331e
ToppCell	5'-Airway_Nasal-Epithelial-Airway_epithelium-respiratory_basal_cell-Basal_resting-Basal_resting_L.0.0.0.0\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	MXRA5 EGFR RASSF6 RFX6	3.90e-04	170	90	4	0cc20322cb3e3e7bbd4daad8785c99f80e355c16
ToppCell	5'-Airway_Nasal-Epithelial-Airway_epithelium-respiratory_basal_cell-Basal_resting\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	MXRA5 EGFR RASSF6 RFX6	3.90e-04	170	90	4	2d880223d01bde4bf777bd6f50b7d2768489075f
ToppCell	ASK454-Immune-NK_cell\|Immune / Donor, Lineage and Cell class of Lung cells from Dropseq	CCDC142 ARHGEF33 DOK2 KIR3DL1	3.90e-04	170	90	4	84705434234bf2fbb5256bd5a1f6ab54c01c5a51
ToppCell	367C-Myeloid-Dendritic-cDC_proliferating_2\|Myeloid / Donor, Lineage, Cell class and subclass (all cells)	UHRF1 E2F1 IQGAP3 RAD54L	3.99e-04	171	90	4	0eea035fde32cc2a75a0d4227911edb5d54ed47e
ToppCell	ASK454-Immune-NK_cell\|ASK454 / Donor, Lineage and Cell class of Lung cells from Dropseq	CCDC142 ARHGEF33 DOK2 KIR3DL1	4.08e-04	172	90	4	c9e738c3540ee09b08805b1cdb66b4a0d9d40d33
ToppCell	FLU-Healthy-5\|Healthy / Virus stimulation, Condition and Cluster	AHRR MAST4 SDR42E1 SKAP2	4.17e-04	173	90	4	8c218ec1ba927e9312f3df5f312395e907ab64ab
ToppCell	FLU-Healthy-5\|FLU / Virus stimulation, Condition and Cluster	AHRR MAST4 SDR42E1 SKAP2	4.17e-04	173	90	4	bd4f06d971f9d138749094047c9337dfbaf5da31
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell_cycling\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	UHRF1 E2F1 IQGAP3 RAD54L	4.26e-04	174	90	4	84da9faff088d05233183b425385beb054c92d1b
ToppCell	ASK428-Immune-B_cell\|ASK428 / Donor, Lineage and Cell class of Lung cells from Dropseq	MSH6 MAEA LEPR ERMN	4.26e-04	174	90	4	b5a7a612a515736cf3489afd0f6ad2054d54526f
ToppCell	343B-Myeloid-Dendritic-cDC_proliferating_2\|343B / Donor, Lineage, Cell class and subclass (all cells)	UHRF1 E2F1 IQGAP3 RAD54L	4.26e-04	174	90	4	a75ba49ccea6bd3d78ada1092b46deb5202c58a5
ToppCell	PND07-Endothelial-Endothelial_blood-vessel-Macrovascular_EC-VEC-VEC_G2M\|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	UHRF1 CDK5RAP2 PPP6R2 IQGAP3	4.26e-04	174	90	4	6c36d607c48267a75ab4da6fb2fe3f931d1b3b52
ToppCell	Hippocampus-Neuronal-Excitatory-eN1(Slc17a7)-eN1_2-Excitatory_Neuron.Slc17a7.Ptgfr_(Postsubiculum)-\|Hippocampus / BrainAtlas - Mouse McCarroll V32	LRGUK RASSF6 TPH2	4.35e-04	73	90	3	27644d9b67ef933af0c77936cabdbd81f05c8562
ToppCell	Hippocampus-Neuronal-Excitatory-eN1(Slc17a7)-eN1_2-Excitatory_Neuron.Slc17a7.Ptgfr_(Postsubiculum)\|Hippocampus / BrainAtlas - Mouse McCarroll V32	LRGUK RASSF6 TPH2	4.35e-04	73	90	3	e97b773931a64f7356f44c6950186f7bbbeb3e8d
ToppCell	facs-Heart-RV-18m-Myeloid\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ARG2 RHBG RPE65 CLUH	4.35e-04	175	90	4	bde002379088c0407afd0f3dae60b6a166683957
Drug	1kel	ARG2 ERBB2 AHRR ARSA EGFR TSC2	8.69e-08	57	88	6	CID000445651
Drug	Iopamidol [60166-93-0]; Down 200; 5.2uM; MCF7; HT_HG-U133A	MAST4 LILRB2 NAB2 TSC2 PPP6R2 PIGZ ZNF574	1.18e-05	198	88	7	7189_DN
Drug	N-(2-(4-((3-chloro-4-(3-(trifluoromethyl)phenoxy)phenyl)amino)-5H-pyrrolo(3,2-d)pyrimidin-5-yl)ethyl)-3-hydroxy-3-methylbutanamide	ERBB2 EGFR	1.48e-05	2	88	2	ctd:C570404
Drug	Lapatinib	ERBB2 EGFR	1.48e-05	2	88	2	DB01259
Drug	1,3-diphosphoglycerate	GALM VCAN MAEA TAPBP	3.56e-05	48	88	4	CID000000683
Drug	pyrido[3,4-d]pyrimidine	ERBB2 EGFR	4.42e-05	3	88	2	CID014758064
Drug	5-iodonicotinic acid	ERBB2 EGFR	4.42e-05	3	88	2	CID000151950
Drug	2-acetamidoethanethiol	ERBB2 EGFR	4.42e-05	3	88	2	ctd:C023704
Drug	4557 W	ERBB2 EGFR	4.42e-05	3	88	2	ctd:C433938
Drug	4-aminopyrimidine-5-carbaldehyde	ERBB2 EGFR	4.42e-05	3	88	2	CID011228787
Drug	tyrphostin AG825	ERBB2 EGFR	8.82e-05	4	88	2	CID000002062
Drug	EGFR/ErbB2 inhibitor	ERBB2 EGFR	8.82e-05	4	88	2	CID009843206
Drug	MS-275; Down 200; 10uM; PC3; HT_HG-U133A	CEP104 MSH6 MICALL2 ZFYVE26 RHOT2 RAD54L	9.31e-05	189	88	6	7074_DN
Drug	17-AAG; Down 200; 1uM; MCF7; HT_HG-U133A_EA	MAST4 ZFYVE26 ASPSCR1 PPP6R2 PIGZ SMAD3	9.87e-05	191	88	6	998_DN
Drug	geldanamycin; Down 200; 1uM; MCF7; HT_HG-U133A	MSH6 ASPSCR1 HCFC1 SMAD3 CLASRP ZNF574	1.04e-04	193	88	6	1653_DN
Drug	geldanamycin; Down 200; 1uM; MCF7; HT_HG-U133A	NAB2 E2F1 ZFYVE26 PRR14L PPP6R2 SMAD3	1.04e-04	193	88	6	5588_DN
Drug	Ethamivan [304-84-7]; Down 200; 18uM; PC3; HT_HG-U133A	ARG2 MAST4 MICALL2 E2F1 SKAP2 PIGZ	1.07e-04	194	88	6	7260_DN
Drug	Alfuzosin hydrochloride [81403-68-1]; Down 200; 9.4uM; PC3; HT_HG-U133A	MSH6 TBC1D9B VCAN TSC2 ASPSCR1 HCFC1	1.11e-04	195	88	6	4644_DN
Drug	Isopropamide iodide [71-81-8]; Down 200; 8.4uM; MCF7; HT_HG-U133A	CTC1 E2F1 PPP6R2 RAD54L SMAD3 CLASRP	1.11e-04	195	88	6	3461_DN
Drug	Nifenazone [2139-47-1]; Down 200; 13uM; PC3; HT_HG-U133A	ARG2 MAST4 E2F1 ASPSCR1 CLUH HCFC1	1.11e-04	195	88	6	2122_DN
Drug	Asiaticoside [16830-15-2]; Down 200; 4.2uM; MCF7; HT_HG-U133A	CEP104 MAST4 CDK5RAP2 E2F1 RHOT2 SMAD3	1.11e-04	195	88	6	3504_DN
Drug	Butylparaben [94-26-8]; Up 200; 20.6uM; MCF7; HT_HG-U133A	CEP104 MAST4 RHBG NAB2 DGKQ DOK2	1.11e-04	195	88	6	5608_UP
Drug	Pantothenic acid calcium salt monohydrate [63409-48-3]; Down 200; 8uM; MCF7; HT_HG-U133A	NAB2 ZFYVE26 RHOT2 PIGZ LEPR SMAD3	1.14e-04	196	88	6	3248_DN
Drug	Hecogenin [467-55-0]; Down 200; 9.2uM; MCF7; HT_HG-U133A	MAST4 NAB2 RHOT2 PPP6R2 HCFC1 CLASRP	1.14e-04	196	88	6	7175_DN
Drug	Furosemide [54-31-9]; Down 200; 12uM; PC3; HT_HG-U133A	EGFR NAB2 CDK5RAP2 E2F1 TSC2 HCFC1	1.17e-04	197	88	6	4503_DN
Drug	Flumequine [42835-25-6]; Down 200; 15.4uM; MCF7; HT_HG-U133A	CEP104 ERBB2 EGFR CTC1 CDK5RAP2 ATG2A	1.20e-04	198	88	6	5529_DN
Drug	ICI 182,780; Up 200; 1uM; ssMCF7; HG-U133A	ARG2 RUNDC3A CDK5RAP2 PRR14L GPATCH8 SMAD3	1.24e-04	199	88	6	523_UP
Drug	Mimosine [500-44-7]; Down 200; 20.2uM; MCF7; HT_HG-U133A	MAST4 CTC1 NAB2 PRR14L PPP6R2 PIGZ	1.24e-04	199	88	6	5302_DN
Drug	2-propylpentanoic acid; Down 200; 50uM; MCF7; HT_HG-U133A	TBC1D9B CDK5RAP2 ASPSCR1 PPP6R2 RAD54L SMAD3	1.24e-04	199	88	6	6982_DN
Drug	estradiol, USP; Down 200; 0.1uM; MCF7; HT_HG-U133A	TBC1D9B MICALL2 CDK5RAP2 TSC2 PPP6R2 ZNF574	1.24e-04	199	88	6	6968_DN
Drug	Esculetin [305-01-1]; Down 200; 22.4uM; MCF7; HT_HG-U133A	MICALL2 RHBG ASPSCR1 HCFC1 CDH10 SMAD3	1.24e-04	199	88	6	6499_DN
Drug	Clorsulon [60200-06-8]; Down 200; 10.6uM; MCF7; HT_HG-U133A	CTC1 NAB2 E2F1 SKAP2 PIGZ SMAD3	1.24e-04	199	88	6	7025_DN
Drug	Furazolidone [67-45-8]; Up 200; 17.8uM; HL60; HT_HG-U133A	ARG2 RUNDC3A RHBG SAGE1 CDH10 LILRA4	1.27e-04	200	88	6	3019_UP
Drug	Oxytetracycline dihydrate [6153-64-6]; Down 200; 8uM; PC3; HT_HG-U133A	FAT4 CTC1 VCAN NAB2 RHOT2 SMAD3	1.27e-04	200	88	6	5772_DN
Disease	Hennekam syndrome (is_implicated_in)	FAT4 ADAMTS3	2.51e-05	3	86	2	DOID:0060366 (is_implicated_in)
Disease	Hennekam lymphangiectasia-lymphedema syndrome	FAT4 ADAMTS3	2.51e-05	3	86	2	C0340834
Disease	oral squamous cell carcinoma (is_marker_for)	TET2 ERBB2 EGFR AXIN2	3.51e-05	63	86	4	DOID:0050866 (is_marker_for)
Disease	Carcinoma of lung	ERBB2 MXRA5 EGFR	4.06e-05	23	86	3	C0684249
Disease	Cetuximab response	ERBB2 EGFR	8.35e-05	5	86	2	cv:CN077967
Disease	Panitumumab response	ERBB2 EGFR	8.35e-05	5	86	2	cv:CN077999
Disease	Nerve Degeneration	ARG2 TSC2 SIRT1 AGTPBP1	1.04e-04	83	86	4	C0027746
Disease	Fibroid Tumor	TSC2 SMAD3	1.25e-04	6	86	2	C0023267
Disease	Uterine Fibroids	TSC2 SMAD3	1.75e-04	7	86	2	C0042133
Disease	colon adenoma (is_marker_for)	TET2 AXIN2	1.75e-04	7	86	2	DOID:0050912 (is_marker_for)
Disease	Adenocarcinoma of large intestine	MSH6 ERBB2 EGFR AXIN2	1.82e-04	96	86	4	C1319315
Disease	Neoplasm Recurrence, Local	TET2 ERBB2 EGFR	2.02e-04	39	86	3	C0027643
Disease	dementia (is_marker_for)	EGFR E2F1	2.32e-04	8	86	2	DOID:1307 (is_marker_for)
Disease	urinary bladder cancer (is_marker_for)	MSH6 ERBB2 EGFR E2F1	2.76e-04	107	86	4	DOID:11054 (is_marker_for)
Disease	Malignant neoplasm of breast	MSH6 ERBB2 TBC1D9B EGFR E2F1 ZFYVE26 CDH10 LEPR SIRT1 RAD54L CLASRP	2.85e-04	1074	86	11	C0006142
Disease	body fat distribution	AHRR MICALL2 ADAMTS3 VCAN SMAD3	3.18e-04	202	86	5	EFO_0004341
Disease	Head and Neck Carcinoma	ERBB2 EGFR	3.72e-04	10	86	2	C3887461
Disease	lung adenocarcinoma (is_implicated_in)	ERBB2 EGFR AXIN2	4.00e-04	49	86	3	DOID:3910 (is_implicated_in)
Disease	gallbladder neoplasm	ERBB2 EGFR	4.54e-04	11	86	2	C0016978
Disease	osteosarcoma (is_marker_for)	MSH6 E2F1	4.54e-04	11	86	2	DOID:3347 (is_marker_for)
Disease	Malignant neoplasm of gallbladder	ERBB2 EGFR	4.54e-04	11	86	2	C0153452
Disease	Papilloma	ERBB2 EGFR	5.44e-04	12	86	2	C0030354
Disease	Papillomatosis	ERBB2 EGFR	5.44e-04	12	86	2	C0205875
Disease	Papilloma, Squamous Cell	ERBB2 EGFR	5.44e-04	12	86	2	C0205874
Disease	Insulin Resistance	EGFR LEPR SIRT1	7.25e-04	60	86	3	C0021655
Disease	Insulin Sensitivity	EGFR LEPR SIRT1	7.25e-04	60	86	3	C0920563
Disease	Neoplasm of lung	ERBB2 EGFR	7.47e-04	14	86	2	cv:C0024121
Disease	median neuropathy (biomarker_via_orthology)	ERBB2 EGFR	7.47e-04	14	86	2	DOID:571 (biomarker_via_orthology)
Disease	Lung cancer	ERBB2 EGFR	7.47e-04	14	86	2	cv:C0242379
Disease	LUNG CANCER	ERBB2 EGFR	7.47e-04	14	86	2	211980
Disease	esterified cholesterol measurement, low density lipoprotein cholesterol measurement	ADAMTS3 RASSF6	7.47e-04	14	86	2	EFO_0004611, EFO_0008589
Disease	acute kidney failure (biomarker_via_orthology)	ARG2 EGFR SIRT1	7.61e-04	61	86	3	DOID:3021 (biomarker_via_orthology)
Disease	carcinoma (implicated_via_orthology)	FAT4 ERBB2 EGFR	8.76e-04	64	86	3	DOID:305 (implicated_via_orthology)
Disease	Alcohol abuse	EGFR TPH2 SIRT1	1.00e-03	67	86	3	C0085762
Disease	Benign neoplasm of stomach	ERBB2 AXIN2	1.11e-03	17	86	2	C0153943
Disease	Neoplasm of uncertain or unknown behavior of stomach	ERBB2 AXIN2	1.11e-03	17	86	2	C0496905
Disease	Carcinoma in situ of stomach	ERBB2 AXIN2	1.11e-03	17	86	2	C0154060
Disease	non-high density lipoprotein cholesterol measurement	CCDC170 AMBN ADAMTS3 RASSF6 DGKQ PPP6R2 SMAD3 ZNF574	1.13e-03	713	86	8	EFO_0005689
Disease	brain measurement, neuroimaging measurement	MAST4 ADAMTS3 EGFR FAT3 VCAN ATOH1 GPATCH8	1.14e-03	550	86	7	EFO_0004346, EFO_0004464
Disease	Non-Small Cell Lung Carcinoma	ERBB2 MXRA5 EGFR E2F1	1.14e-03	156	86	4	C0007131
Disease	Malignant neoplasm of endometrium	MSH6 EGFR	1.25e-03	18	86	2	C0007103
Disease	Carcinoma in situ of endometrium	MSH6 EGFR	1.25e-03	18	86	2	C0346191
Disease	laryngeal squamous cell carcinoma (is_marker_for)	ERBB2 EGFR	1.39e-03	19	86	2	DOID:2876 (is_marker_for)
Disease	fasting blood glucose measurement	FAT3 TPH2 RFX6 ADGRL2 LEPR	1.54e-03	287	86	5	EFO_0004465
Disease	Retinal Degeneration	ARG2 RPE65	1.70e-03	21	86	2	C0035304
Disease	Left Ventricle Remodeling	SMAD3 AXIN2	1.70e-03	21	86	2	C0600520
Disease	Ventricular Remodeling	SMAD3 AXIN2	1.70e-03	21	86	2	C0600519
Disease	Stomach Carcinoma	ERBB2 AXIN2	1.70e-03	21	86	2	C0699791
Disease	Autism Spectrum Disorders	USH2A IQGAP3 CDH10	1.99e-03	85	86	3	C1510586
Disease	forced expiratory volume	TET2 UHRF1 RFX6 ASPSCR1 ADGRL2 PPP6R2 SKAP2 SMAD3	2.14e-03	789	86	8	EFO_0004314
Disease	Intrahepatic Cholangiocarcinoma	ERBB2 EGFR	2.22e-03	24	86	2	C0345905
Disease	Extrahepatic Cholangiocarcinoma	ERBB2 EGFR	2.22e-03	24	86	2	C3805278
Disease	Lynch syndrome (is_implicated_in)	MSH6 SMAD3	2.22e-03	24	86	2	DOID:3883 (is_implicated_in)
Disease	malaria (is_implicated_in)	KIR3DL1 KIR3DS1	2.22e-03	24	86	2	DOID:12365 (is_implicated_in)
Disease	attention deficit hyperactivity disorder, substance abuse, antisocial behaviour measurement	TET2 MSH6 LRGUK ASPSCR1 RHOT2 ADGRL2 USH2A PDZRN3	2.35e-03	801	86	8	EFO_0003888, EFO_0007052, MONDO_0002491
Disease	Impaired glucose tolerance	LEPR SIRT1	2.41e-03	25	86	2	C0271650
Disease	Brain Diseases	CTC1 TSC2	2.41e-03	25	86	2	C0006111
Disease	birth weight, parental genotype effect measurement	TET2 RFX6 ASPSCR1 SMAD3	2.43e-03	192	86	4	EFO_0004344, EFO_0005939
Disease	Cholangiocarcinoma	ERBB2 EGFR	2.61e-03	26	86	2	C0206698
Disease	Squamous cell carcinoma of esophagus	FAT4 EGFR FAT3	2.73e-03	95	86	3	C0279626
Disease	mean fractional anisotropy measurement	TBC1D9B EGFR VCAN	2.73e-03	95	86	3	EFO_0008399
Disease	Retinal Diseases	RPE65 SIRT1	2.81e-03	27	86	2	C0035309
Disease	retinitis pigmentosa (implicated_via_orthology)	USH2A AGTPBP1	2.81e-03	27	86	2	DOID:10584 (implicated_via_orthology)
Disease	Encephalopathies	CTC1 TSC2	2.81e-03	27	86	2	C0085584

Protein segments in the cluster

Peptide	Gene	Start	Entry
YPHPPTVLLGEDLSS	nan	86	A4D1N5
AELDHLASLLPFPPD	AHRR	46	A9YTQ3
LPTHDPSPLQRYSED	ERBB2	1101	P04626
YHDPPLLFDISRDPS	ARSH	476	Q5FYA8
YLEPGLLEHAISPSA	ASPSCR1	471	Q9BZE9
TSFNSPHLYPPEELI	nan	96	Q9N2K0
TSFNSPHLYPPEELI	nan	96	Q9N2J8
HIVYDQLPTPSSPDE	ARG2	331	P78540
HYPPATLDSFLVLEP	C8orf86	141	Q6ZUL3
LDVYIEDPHLPPSLG	CTC1	946	Q2NKJ3
EEYLHITEPPSLSPD	VCAN	2881	P13611
LENPAFLTELEPAPH	AMBN	336	Q9NP70
PSAPLASPEQEIEHY	FAT4	4606	Q6V0I7
GIHSEELLQPYPSAP	ARHGEF33	491	A8MVX0
LPPGLSPEEYSSLLH	DGKQ	506	P52824
HPLSLLPSGSYEEDP	AXIN2	421	Q9Y2T1
YLTDPVLFTLPHIDP	ADGRL2	766	O95490
DLPPLLHEAEALYSL	CCDC142	461	Q17RM4
VEVPDGPTLHDPDLY	AGTPBP1	616	Q9UPW5
AVDDYPLPSHLDLPS	ATG2A	996	Q2TAZ0
HVDTEKPYPASIPEL	ASXL3	841	Q9C0F0
YLDPHTTQPAVEPTD	ATG4B	276	Q9Y4P1
LTYQHLLPESPEPSA	CDK5RAP2	1341	Q96SN8
LDPYLLPEEHPSAHE	PDZRN3	381	Q9UPQ7
EDGIVLDLPLYPAHP	PBLD	116	P30039
PHAKDEPDSPVLYRT	RASSF6	171	Q6ZTQ3
DALVLYEPPPLSAHD	RAD54L	116	Q92698
YEPPPLSAHDQLKLD	RAD54L	121	Q92698
LPPYSDIHDPLNILD	RFX6	831	Q8HWS3
LYPPEGAHVPDSTLL	IQCM	431	A0A1B0GVH7
THYFLPPDDAVPSDD	HCFC1	1826	P51610
DSIEETLPPRPDHIY	DOK2	331	O60496
SNPYLLSHPSEPLEL	LILRA4	401	P59901
PPDTHISPYKDLLDP	MAEA	246	Q7L5Y9
VPPYRPSLEEDSASL	NAB2	401	Q15742
IIDPLPPIDHSEIDY	DDX42	196	Q86XP3
HTPYQLSAPSDPLDI	KIR3DL1	201	P43629
SPVRLHPDYLSPEEI	MICALL2	726	Q8IY33
ESSLLPIAPDLEHFP	GPATCH8	1266	Q9UKJ3
HLPYELSAPSDPLDI	KIR3DL3	201	Q8N743
NSDPYLLSHPSEPLE	LILRB2	401	Q8N423
LYCSDIPSIHPISEP	LEPR	471	P48357
YDPPPEVVAAQDHLT	LRGUK	376	Q96M69
TAHEPPLLYDLSKDP	ARSA	421	P15289
PDHPDFDASTLYVPE	MSH6	386	P52701
VDSPLPHYRVEPSLE	ERMN	36	Q8TAM6
LPYDVTPEQALSHPE	IQGAP3	1096	Q86VI3
PHTAAAIPPDYLLDL	NDOR1	361	Q9UHB4
PPVLLRPGEEYDHTT	GALM	321	Q96C23
FTHTPPLDPQELDIL	EGFR	381	P00533
EDHYFLLTEPPLNTP	ACTR3	106	P61158
TLPPPYLLEAAETHD	ADAMTS3	1056	O15072
TDPHPKINAESLPYD	CEP104	366	O60308
PEEFISLSPPHEALD	E2F1	396	Q01094
GDESLPYLPLHLHPD	SDR42E1	136	Q8WUS8
HDDPSLVPNVPYFDL	CHERP	636	Q8IWX8
HDLDPTAPPYDSLAT	CDH10	721	Q9Y6N8
TIPYELPPHSPFLDD	FBXO15	331	Q8NCQ5
IDSEYPPPHEEEFLS	FAT3	4401	Q8TDW7
HPVYPPELSLLDSTD	ATOH1	46	Q92858
APSPADPLLSFHLDL	CDC42EP5	81	Q6NZY7
LPYQPTPDELHFLSK	MAST4	316	O15021
RGPAHELALEPDSPY	DCAF8L1	286	A6NGE4
PAPEETYDHLSEVPV	CCDC170	16	Q8IYT3
SLLSLLYDFLDHEPP	PPP6R2	101	O75170
LLLPSPEFDYRPESE	PRR14L	596	Q5THK1
STSEDNSPEHPYLPL	RUNDC3A	226	Q59EK9
NSPEHPYLPLVTDED	RUNDC3A	231	Q59EK9
LLPGLPHPYSDLADV	RTL1	551	A6NKG5
LYTAQLPPEHVDSPV	USH2A	2136	O75445
YPSEPIFVSHPDALE	RPE65	466	Q16518
ELTADYLSPLIHVPP	RHOT2	281	Q8IXI1
LYDDVDHPLPISNPL	SKAP2	236	O75563
HTPYQLSAPSDPLDI	KIR3DS1	201	Q14943
LAYLSELPPTPLHVS	SIRT1	521	Q96EB6
LHLPPALSPEEAESA	TBC1D9B	926	Q66K14
LDHIPDYTPPLLTTI	CLASRP	86	Q8N2M8
SYPNPVAHLPADELV	CLUH	851	O75153
EDEELYPDIHPPPSL	TRIM52	161	Q96A61
HPLLLEDSPSCPSLY	TRPM5	936	Q9NZQ8
KLPFLDSPPDSQHYE	RHBG	416	Q9H310
PTPPEELHAAAYVFT	SAGE1	11	Q9NXZ1
EDPALSPHLLLPDSL	TRABD2B	401	A6NFA1
IPAEFPPLDDYSHSI	SMAD3	146	P84022
PRPDLDPELYLSVHD	TAPBP	56	O15533
PDPLPASDHSYELRN	ZNF574	266	Q6ZN55
LHSDRDPIPDVPAVY	SCFD1	76	Q8WVM8
ETLLFPHLTLEDPPA	PIGZ	541	Q86VD9
SDPLYTPEPDTCHEL	TPH2	306	Q8IWU9
IPDLSKPLLDHSYDP	FTSJ1	206	Q9UET6
HIYCLDPPLSSVPSE	UHRF1	341	Q96T88
SPHSPATLDYALEDP	TSPYL6	6	Q8N831
REPAEPHETSEPTYL	TET2	1951	Q6N021
DLEFHLLEPVPSSPL	PRR23C	216	Q6ZRP0
SADLHPEPHLPEDYA	ZFYVE26	586	Q68DK2
EEAAYSNPSLPLVHP	TSC2	1756	P49815
EPYEPSPTLHTLDTV	MXRA5	916	Q9NR99